Researcher:
Mandel, Nil Molinas

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Nil Molinas

Last Name

Mandel

Name

Name Variants

Mandel, Nil Molinas

Email Address

Birth Date

Filters

2013 - 2019202020 - 20239

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.4ce60fb4-08bb-43be-a45e-13c49f878275

Search Results

Now showing 1 - 10 of 29
  • Placeholder
    PublicationMetadata only
    Is alveolar spread may be predictive with PET CT scanning?
    (Elsevier Science inc, 2017) Zeren, Handan; Selçukbiricik, Fatih; Mandel, Nil Molinas; Tanju, Serhan; Falay, Fikri Okan; Bulutay, Pınar; Zeren, Emine Handan; Erus, Suat; Dilege, Şükrü; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; Teaching Faculty; N/A; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; 202015; 194197; 214690; 246484; 133565; N/A; 175565; 22573
    Background: In this study we aim to investigate predictability of alveolar spread in primary lung cancer by using preoperatively scanning methods. Method: In order to re-evaluate alveolar spread, pathology preparations of 45 patients had operated for primary lung cancer diagnosis and scanned preoperatively with PET CT all in our hospital which interpreted by same nuclear medicine specialists implicated in this study. As using the patients pet CT findings, CTV (computerized tomography volume), MTV (metabolic tumor volume), TLG(total lesion glycolysis), SUDmax, SUDort values and their relation with alveolar spread analyzed. Result: Preoperatively PET-CT scanned all in our hospital 45 patients has included and cause of couldn't reach their pathological preparations, 6 of them exluded from the study. 21 of 39 patients were men (53.8%) , 18 of them were women (46.2%) and mean age was 66.67/+-7.88 (42-80). We didn't detect any relation between CTV, MTV, TLG, SUDmax, SUDort values and alveolar spread (p>0.05). However when the CTV/ MTV ratio analyzed, alveolar spread was statistically more common in the group of patients had ratio lower than 1. (62.9% versus 0%, p:0.01). Conclusion: High local recurrence risk in sublober rejected patients with alveolar spread has indicated in various studies. Regarding this matter, we recommend re-evaluation of the patients for sublober rejections whose CTV/MTV ratio is lower than 1.
  • Placeholder
    PublicationMetadata only
    Neoadjuvant hormonal therapy in breast cancer
    (Springer, 2016) Selcukbiricik, Fatih; Mandel, Nil Molinas; Faculty Member; School of Medicine; 194197
    The various types of ER-positive and HER-2-negative breast cancers have different treatment modalities. There are two options for the treatment of locally advanced breast cancer: chemotherapy or hormonal therapy. Chemotherapy can be particularly toxic for elderly postmenopausal patients, and neoadjuvant hormonal therapy (NHT) is an alternative for patients with hormone receptor-positive, locally advanced, postmenopausal breast cancer. This treatment is also highly beneficial for patients with comorbidities and can comprise tamoxifen and steroidal or nonsteroidal aromatase inhibitors (AIs). The best activities in clinical trials are observed with AIs. NHT produces good response rates (RRs) as well as adequate downstaging of tumor size such that breast-conserving surgery (BCS) may become an option. The optimal duration of such treatments should not be less than 4 months and may be continued for as long as 8 months.
  • Placeholder
    PublicationMetadata only
    Relation of visceral pleura invasion with hilar lymph node involvement and survival in primary lung cancer
    (Elsevier Science Inc, 2015) Bayrak, Yusuf; Tanju, Serhan; Erus, Suat; Mandel, Nil Molinas; Dilege, Şükrü; Faculty Member; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; 214690; 175565; 194197; 122573
    N/A
  • Placeholder
    PublicationMetadata only
    The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: a Turkish Oncology Group Study
    (Imprimatur Publications, 2021) Ak, Naziye; Özkan, Berker; Yenigün, Mustafa B.; Yılmazbayhan, Dilek; Toker, Alper; Ferhatoğlu, Ferhat; Yaşar, Arzu; Sak, Serpil Dizbay; Kılıçkap, Sadettin; Önder, Sevgen; Dikmen, Erkan; Alan, Özkan; Yumuk, Perran F.; Bozkurtlar, Emine; Laçin, Tunç; Yıldızeli, Bedrettin; Özturk, Akın; Ürer, Nur; Oyan, Başak; Aydıner, Adnan; Demirkazık, Ahmet; Eralp, Yeşim; Kocatürk, Celalettin; Karapınar, Kemal; Tanju, Serhan; Dilege, Şükrü; Erus, Suat; Bulutay, Pınar; Fırat, Pınar Arıkan; Mandel, Nil Molinas; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 214690; 122573; 175565; 133565; 207545; 194197
    Purpose: The benefit of adjuvant chemotherapy for tumors smaller than 4 cm is not clear. We aimed to evaluate the prognostic impact of adjuvant platin-based chemotherapy in high-risk stage I patients with non-small cell lung cancer (NSCLC). Methods: This cooperative group study included 232 NSCLC patients who underwent curative surgery for stage I disease with tumor size 2-4 cm. Results: Median age at presentation was 63 years (range 18-90). The mean tumor size was 29.6 +/- 7.3 mm. The frequency of patients with specified risk factors were: visceral pleural effusion (VPI): n: 82 (36.6%); lymphovascular invasion (LVI): n: 86 (39.1%); Grade 3: n: 48 (32.7%); Solid micropapillary pattern (SMP): n: 70 (48.3%). Adjuvant platin-based chemotherapy was administered to 51 patients. During a median follow-up period of 50.5 months 68 patients (29.3%) developed recurrence, 54 (23.3%) died from any cause and 38 (16.4%) of them died of lung cancer. Patients who received chemotherapy compared with the non-chemotherapy group had a longer 5-years relapse-free survival (RFS) (84.5 vs. 61.1%). Also on multivariate analysis, adjuvant chemotherapy was a significant independent prognostic factor for RFS. Conclusion: Adjuvant platin-based chemotherapy should be considered for patients with small tumors with adverse risk factors.
  • Placeholder
    PublicationMetadata only
    Low regrowth after cCR in non-operative TNT management of locally advanced rectal cancer patients
    (Elsevier Ireland Ltd, 2022) N/A; N/A; N/A; N/A; N/A; N/A; N/A; Selek, Uğur; Selçukbiricik, Fatih; Özoran, Emre; Balık, Emre; Bölükbaşı, Yasemin; Mandel, Nil Molinas; Buğra, Dursun; Faculty Member; Faculty Member; Teaching Faculty; Faculty Member; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 27211; 202015; 307296; 18758; 216814; 194197; 1758
    N/A
  • Placeholder
    PublicationMetadata only
    Neoadjuvant and adjuvant treatment results in non-small cell lung cancer
    (Sakarya Üniversitesi, 2020) Cengiz, Hasret; Demirci, Ayşe; Varım, Ceyhun; Turna, Hande; N/A; Mandel, Nil Molinas; Faculty Member; School of Medicine; 194197
    Objective : In this study we assess our center’s neoadjuvant and adjuvant therapy results in terms of disease free and overall survival and determine the effects of patient and tumor characteristics as prognostic factors in patients with early stage Non Small Cell Lung Cancer NSCLC. Materials and methods Files of 182 patients in stage I-III NSCLC followed up at outpatient Medical Oncology Clinic of Cerrahpaşa Medical Faculty, between January 2005 and June 2010 were retrospectively analysed. Patient and tumor characteristics; disease free and overall survival, the prognostic effects of patient and tumor characteristics on survival were analysed. Results Neoadjuvant chemotherapy group consisted of 47 patients, however 135 patients had primary surgery and had either received adjuvan chemotherapy or followed-up without therapy. Adjuvant chemotherapy improved disease free survival (p=0.001) and overall survival significantly (p<0.001) in stage III NSCLC patients. In the neoadjuvant therapy group the response rate was found to be 25.5% and 23.4% of patients could be operated. No survival benefit was found between stage III NSCLC patients receiving neoadjuvant chemotherapy or not. The patients who could be operated after neoadjuvant chemotherapy were found to have a longer overall survival than the patients who couldn’t. (43.9 ±5.8 months vs 20.2±1.7months). Conclusion Adjuvant chemotherapy improved survival only at stage III. The lack of benefit in stage II, can be due to relatively smaller benefit and inefficient number of patients to show this small benefit at this stage. Neoadjuvant chemotherapy was found beneficial only when it reduced the mediastinal nodal stage. Tumor diameter, vascular invasion and chest wall invasion were found to be the pathological characteristics that have a statistically significant impact in terms of disease free and overall survival. / Amaç Kliniğimize Küçük Hücreli Dışı Akciğer Kanseri (KHDAK) tanısı ile başvuran ve bu tanı ile neoadjuvan ve adjuvan tedavi alan hastaların hastalıksız ve genel sağkalım sonuçlarını değerlendirmek ve erken evre KHDAK’de hasta ve tümör karakteristiklerinin prognoza etkisini belirlemektir. Gereç ve Yöntemler Kliniğimize Ocak 2005-Haziran 2010 tarihleri arasında başvuran KHDAK hastalarının dosyaları retrospektif olarak taranarak, hasta ve tümör karakteristikleri, hastalıksız ve genel sağkalım verileri, hasta ve tümör özelliklerinin prognoza etkisi incelendi. Bulgular Neoadjuvan grup 47 hastadan, primer opere olan grup da 135 hastadan oluşuyordu. Cisplatin bazlı adjuvan kemoterapi evre III hastalarda hem hastalıksız sağkalım (p=0,001) ve hem de genel sağkalım (p<0.001) açısından anlamlı yarar sağlandı. Neoadjuvan tedavi grubunda cevap oranı %25,5 idi ve %23,4 hasta opere olabildi. Neoadjuvan tedavi alan evre III grup hastalar aynı evredeki adjuvan grup ile karşılaştırıldığında sağkalım azalması bulunamazken; tedavi sonucunda nodal evresi gerileyip opere olabilmiş hastalarda belirgin sağkalım artışı saptandı (43,9±5,8 aya 20,2±1,7 ay). Sonuç Adjuvan kemoterapi sağkalımı sadece evre III hastalarda anlamlı arttırmıştır. Neoadjuvan tedavi eğer mediastinal nodal evreyi geriletiyorsa sağkalım avantajı sağlamıştır. Tümör çapı,vasküler invazyon ve göğüs duvarı invazyonu; hastalıksız ve genel sağkalım açısından önemli tümör karakteristikleri olarak saptanmıştır.
  • Placeholder
    PublicationMetadata only
    Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy
    (Elsevier, 2016) Arf, Serra; Sayman Muslubaş, Işıl; N/A; N/A; N/A; N/A; N/A; Uludağ, Günay; Önal, Sumru; Selçukbiricik, Fatih; Akbay, Aylin Koç; Mandel, Nil Molinas; Doctor; Other; Faculty Member; Doctor; Faculty Member; N/A; School of Medicine; School of Medicine; N/A; School of Medicine; Koc University Hospital; N/A; N/A; Koc University Hospital; N/A; N/A; 52359; 202015; N/A; 194197
    Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and negative work-up for cancer was diagnosed with npAIR. Visual acuity and ancillary tests were normal except abnormal ERG in both eyes. The patient was given one course of rituximab 375 mg/m2/week for 4 weeks and cyclophosphamide 1 gr/m2/month for 6 months. A second course of rituximab was necessary as autoantibody titers showed no change and as new antibodies were noted after treatment with rituximab and cyclophosphamide. Electroretinography was repeated after the first course of rituximab, after cyclophosphamide, and the second course of rituximab therapy. Conclusions and Importance: Rituximab therapy led to marked improvement in full-field ERG readings and regression of symptoms was reported by the patient after rituximab infusions. The effect of rituximab in npAIR was objectively demonstrated with ERG.
  • Placeholder
    PublicationMetadata only
    18F-FDG PET/CT imaging in a patient with a rare diagnosis of sarcomatoid malignant peritoneal mesothelioina
    (Lippincott Williams & Wilkins, 2013) Tokmak, Handan; Demirkol, Onur M.; Kaban, Kerim; N/A; Mandel, Nil Molinas; Dilege, Şükrü; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 194197; 122573
    Malignant peritoneal mesothelioma is an uncommon but deadly disease arising from serosal surfaces of the peritoneum. Asbestos exposure is the most recognized risk factor. We report a case of diffuse, sarcomatoid malignant peritoneal mesothelioma who presented to the hospital with abdominal pain. The patient had an abdominal MRI scan as initial scanning which demonstrated nonspecific findings suspected of peritoneal carcinomatosis. The patient was admitted to our department for the metabolic characterization of the lesions with F-18-FDG PET/CT imaging and the diagnosis of the primary malignancy. F-18-FDG PET/CT imaging revealed diffusely increased metabolic activity throughout the peritoneum and the histopathological features were compatible with sarcomatoid malignant peritoneal mesothelioma.
  • Placeholder
    PublicationMetadata only
    Induction chemotherapy increases the survival of patients with primary neuroectodermal tumors of the thorax
    (Elsevier Science Inc, 2015) Demir, Adalet; Turna, Akif; Hekimoğlu, Elvin; Toker, Alper; Turna, Zeynep Hande; Kaynak, Kamil; Mandel, Nil Molinas; Faculty Member; School of Medicine; 194197
    N/A
  • Placeholder
    PublicationMetadata only
    Optimizing the personalized care for the management of rectal cancer: a consensus statement
    (Aves, 2022) Aytaç, Erman; Özer, Leyla; Baca, Bilgi; Uluç, Başak Oyan; Abacioğlu, Mehmet Ufuk; Gönenç, Murat; Aygün, Cem; Yıldız, Mehmet Erdem; Ünal, Kemal; Er, Özlem; Beşe, Nuran; Ceyhan, Güralp Onur; Özbek, Uğur; Tozun, Nurdan; Erdamar, Sibel; Yakıcıer, Cengiz; Saruç, Murat; Özben, Volkan; Esen, Eren; Vardareli, Erkan; Güner, Levent; Hamzaoğlu, İsmail; Karahasanoğlu, Tayfun; N/A; Balık, Emre; Kapran, Yersu; Taşkın, Orhun Çığ; Bölükbaşı, Yasemin; Çil, Barbaros Erhan; Baran, Bülent; Erkol, Burçak; Yaltı, Mehmet Tunç; Attila, Tan; Gürses, Bengi; Bilge, Orhan; Mandel, Nil Molinas; Selek, Uğur; Kayserili, Hülya; Özoran, Emre; Buğra, Dursun; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; N/A; N/A; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 18758; 168101; 166686; 216814; 169993; 167583; N/A; 221690; 118342; 113169; 176833; 194197; 27211; 7945; 307296; 1758
    Colorectal cancer is the third most common cancer in Turkey. The current guidelines do not provide sufficient information to cover all aspects of the management of rectal cancer. Although treatment has been standardized in terms of the basic principles of neoadjuvant, surgical, and adjuvant therapy, uncertainties in the management of rectal cancer may lead to significant differences in clinical practice. In order to clarify these uncertainties, a consensus program was constructed with the participation of the physicians from the Acibadem Mehmet Ali Aydınlar and Koc Universities. This program included the physicians from the departments of general surgery, gastroenterology, pathology, radiology, nuclear medicine, medical oncology, radiation oncology, and medical genetics. The gray zones in the management of rectal cancer were determined by reviewing the evidence-based data and current guidelines before the meeting. Topics to be discussed consisted of diagnosis, staging, surgical treatment for the primary disease, use of neoadjuvant and adjuvant treatment, management of recurrent disease, screening, follow-up, and genetic counseling. All those topics were discussed under supervision of a presenter and a chair with active participation of related physicians. The consensus text was structured by centralizing the decisions based on the existing data.